NYSE:MD - MEDNAX Stock Price, Price Target & More

$51.03 -0.97 (-1.87 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$51.03
Today's Range$50.95 - $52.04
52-Week Range$40.56 - $63.04
Volume536,632 shs
Average Volume718,707 shs
Market Capitalization$4.88 billion
P/E Ratio16.20
Dividend YieldN/A
Beta0.23

About MEDNAX (NYSE:MD)

MEDNAX logoMEDNAX, Inc. is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company's national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. As of December 31, 2016, the Company had over 1,390 affiliated physicians providing anesthesia care to patients in connection with surgical and other procedures, as well as pain management. As of December 31, 2016, the Company had 270 affiliated physicians providing maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.

Receive MD News and Ratings via Email

Sign-up to receive the latest news and ratings for MD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Hospitals
Sub-IndustryHealth Care Services
SectorMedical
SymbolNYSE:MD
CUSIP58502B10
Phone954-384-0175

Debt

Debt-to-Equity Ratio0.60%
Current Ratio1.18%
Quick Ratio1.18%

Price-To-Earnings

Trailing P/E Ratio16.20
Forward P/E Ratio12.79
P/E Growth1.3

Sales & Book Value

Annual Sales$3.46 billion
Price / Sales1.38
Cash Flow$4.20 per share
Price / Cash12.15
Book Value$32.74 per share
Price / Book1.56

Profitability

EPS (Most Recent Fiscal Year)$3.15
Net Income$320.37 million
Net Margins9.26%
Return on Equity10.10%
Return on Assets5.23%

Miscellaneous

Employees7,675
Outstanding Shares93,800,000

How to Become a New Pot Stock Millionaire

MEDNAX (NYSE:MD) Frequently Asked Questions

What is MEDNAX's stock symbol?

MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

How were MEDNAX's earnings last quarter?

MEDNAX Inc (NYSE:MD) posted its quarterly earnings data on Thursday, February, 8th. The company reported $0.87 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.83 by $0.04. The business earned $910.82 million during the quarter, compared to the consensus estimate of $884.55 million. MEDNAX had a return on equity of 10.10% and a net margin of 9.26%. MEDNAX's quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.00 earnings per share. View MEDNAX's Earnings History.

When is MEDNAX's next earnings date?

MEDNAX is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for MEDNAX.

What guidance has MEDNAX issued on next quarter's earnings?

MEDNAX updated its first quarter earnings guidance on Thursday, February, 8th. The company provided earnings per share guidance of $0.84-0.89 for the period, compared to the Thomson Reuters consensus estimate of $0.79.

What price target have analysts set for MD?

13 analysts have issued twelve-month price objectives for MEDNAX's shares. Their predictions range from $47.00 to $62.00. On average, they anticipate MEDNAX's share price to reach $55.3333 in the next year. View Analyst Ratings for MEDNAX.

Who are some of MEDNAX's key competitors?

Who are MEDNAX's key executives?

MEDNAX's management team includes the folowing people:
  • Cesar L. Alvarez, Chairman of the Board (Age 69)
  • Joseph M. Calabro, President, Chief Operating Officer (Age 56)
  • Roger J. Medel M.D., Chief Executive Officer, Director (Age 70)
  • Vivian Lopez-Blanco, Chief Financial Officer, Treasurer (Age 59)
  • David A. Clark, President - MEDNAX National Medical Group Division (Age 50)
  • John C. Pepia, Senior Vice President, Chief Accounting Officer (Age 54)
  • Dominic J. Andreano, Senior Vice President, General Counsel, Secretary (Age 48)
  • Manuel Kadre, Lead Independent Director (Age 51)
  • Karey D. Barker, Independent Director (Age 49)
  • Waldemar A. Carlo M.D., Independent Director (Age 64)

Has MEDNAX been receiving favorable news coverage?

Headlines about MD stock have been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MEDNAX earned a media sentiment score of 0.18 on Accern's scale. They also assigned news articles about the company an impact score of 46.79 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of MEDNAX?

Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MEDNAX's stock price today?

One share of MD stock can currently be purchased for approximately $51.03.

How big of a company is MEDNAX?

MEDNAX has a market capitalization of $4.88 billion and generates $3.46 billion in revenue each year. The company earns $320.37 million in net income (profit) each year or $3.15 on an earnings per share basis. MEDNAX employs 7,675 workers across the globe.

How can I contact MEDNAX?

MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected]


MarketBeat Community Rating for MEDNAX (MD)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  324 (Vote Outperform)
Underperform Votes:  356 (Vote Underperform)
Total Votes:  680
MarketBeat's community ratings are surveys of what our community members think about MEDNAX and other stocks. Vote "Outperform" if you believe MD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MEDNAX (NYSE:MD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
13 Wall Street analysts have issued ratings and price targets for MEDNAX in the last 12 months. Their average twelve-month price target is $55.3333, suggesting that the stock has a possible upside of 8.43%. The high price target for MD is $62.00 and the low price target for MD is $47.00. There are currently 1 sell rating, 9 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.152.172.172.08
Ratings Breakdown: 1 Sell Rating(s)
9 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $55.3333$55.1818$53.8182$55.4444
Price Target Upside: 8.43% upside3.78% downside2.45% upside31.11% upside

MEDNAX (NYSE:MD) Consensus Price Target History

Price Target History for MEDNAX (NYSE:MD)

MEDNAX (NYSE:MD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/27/2018Credit Suisse GroupInitiated CoverageNeutral$57.00LowView Rating Details
3/15/2018Jefferies GroupSet Price TargetHold$58.00LowView Rating Details
2/12/2018BMO Capital MarketsBoost Price TargetMarket Perform -> Market Perform$46.00 -> $58.00LowView Rating Details
2/12/2018JPMorgan ChaseBoost Price TargetNeutral -> Neutral$46.00 -> $55.00LowView Rating Details
2/9/2018MizuhoReiterated RatingNeutral -> Neutral$49.00 -> $53.00LowView Rating Details
2/9/2018Robert W. BairdBoost Price TargetNeutral -> Neutral$48.00 -> $54.00MediumView Rating Details
2/8/2018StephensSet Price TargetBuy$62.00MediumView Rating Details
1/24/2018Stifel NicolausReiterated RatingHold$56.00LowView Rating Details
12/21/2017SunTrust BanksSet Price TargetHold$55.00MediumView Rating Details
12/13/2017Piper JaffrayInitiated CoverageOverweight -> Overweight$58.00LowView Rating Details
11/3/2017CitigroupLower Price TargetNeutral$52.00 -> $47.00N/AView Rating Details
11/1/2017KeyCorpSet Price TargetBuy$51.00N/AView Rating Details
5/4/2017Bank of AmericaDowngradeBuy -> UnderperformLowView Rating Details
12/9/2016Goldman SachsInitiated CoverageNeutral$66.00N/AView Rating Details
10/27/2016Raymond JamesDowngradeOutperform -> Market PerformN/AView Rating Details
10/27/2016UBSDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

MEDNAX (NYSE:MD) Earnings History and Estimates Chart

Earnings by Quarter for MEDNAX (NYSE:MD)

MEDNAX (NYSE:MD) Earnings Estimates

2018 EPS Consensus Estimate: $3.91
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.78$0.80$0.79
Q2 20182$0.97$1.02$1.00
Q3 20182$1.06$1.06$1.06
Q4 20182$1.03$1.09$1.06

MEDNAX (NYSE MD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018$0.82N/AView Earnings Details
2/8/2018Q4 2017$0.8330$0.87$884.55 million$910.82 millionViewN/AView Earnings Details
11/1/2017Q3 2017$0.87$0.87$864.78 million$868.95 millionViewN/AView Earnings Details
7/28/2017Q2 2017$0.81$0.85$849.49 million$843.00 millionViewN/AView Earnings Details
5/4/2017Q1 2017$0.7440$0.75$837.01 million$835.60 millionViewN/AView Earnings Details
4/20/2017Q1 2017$0.81$0.70$839.25 million$836.00 millionViewN/AView Earnings Details
2/7/2017Q416$1.06$1.00$842.15 million$831.00 millionViewListenView Earnings Details
10/27/2016Q316$1.05$1.09$821.18 million$828.00 millionViewListenView Earnings Details
7/28/2016Q216$1.07$1.03$775.68 million$772.00 millionViewListenView Earnings Details
4/28/2016Q116$0.86$0.87$741.49 million$752.60 millionViewListenView Earnings Details
2/4/2016Q415$1.10$1.13$748.02 million$742.00 millionViewListenView Earnings Details
10/29/2015Q315$0.97$1.10$730.63 million$722.30 millionViewListenView Earnings Details
7/30/2015Q215$0.88$0.97$677.02 million$676.60 millionViewListenView Earnings Details
4/30/2015Q115$0.71$0.72$641.24 million$639.40 millionViewListenView Earnings Details
1/29/2015Q414$0.87$0.89$637.90 million$651.00 millionViewListenView Earnings Details
10/30/2014Q314$0.85$0.86$619.61 million$627.00 millionViewListenView Earnings Details
7/31/2014Q214$0.78$0.79$603.00 million$595.54 millionViewListenView Earnings Details
5/1/2014Q114$0.63$0.63$574.80 million$566.00 millionViewListenView Earnings Details
1/30/2014Q4$0.75$0.20$555.30 million$567.00 millionViewListenView Earnings Details
10/31/2013Q313$1.48$1.52$556.63 million$555.00 millionViewListenView Earnings Details
7/30/2013Q2 2013$1.36$1.37$533.39 million$529.18 millionViewListenView Earnings Details
5/2/2013Q1 2013$1.09$1.10$504.24 million$502.70 millionViewListenView Earnings Details
1/31/2013Q4 2012$1.30$1.32$473.70 million$471.30 millionViewListenView Earnings Details
11/1/2012Q312$1.28$1.32$470.60 million$473.10 millionViewN/AView Earnings Details
7/31/2012$1.19$1.22ViewN/AView Earnings Details
5/3/2012$1.00$0.98ViewN/AView Earnings Details
2/2/2012$1.19$1.19ViewN/AView Earnings Details
11/1/2011$1.18$1.19ViewN/AView Earnings Details
8/2/2011$1.15$1.15ViewN/AView Earnings Details
5/3/2011$0.91$0.94ViewN/AView Earnings Details
2/3/2011$1.12$1.12ViewN/AView Earnings Details
11/2/2010Q3 2010$0.53$0.53ViewN/AView Earnings Details
8/3/2010Q2 2010$0.51$0.52ViewN/AView Earnings Details
5/3/2010Q1 2010$0.41$0.41ViewN/AView Earnings Details
2/5/2010Q4 2009$0.49$0.50ViewN/AView Earnings Details
11/2/2009Q3 2009$0.48$0.52ViewN/AView Earnings Details
8/4/2009Q2 2009$0.43$0.47ViewN/AView Earnings Details
5/7/2009Q1 2009$0.33$0.37ViewN/AView Earnings Details
2/5/2009Q4 2008$0.39$0.41ViewN/AView Earnings Details
11/5/2008Q3 2008$0.41$0.41ViewN/AView Earnings Details
8/5/2008Q2 2008$0.39$0.40ViewN/AView Earnings Details
5/8/2008Q1 2008$0.34$0.33ViewN/AView Earnings Details
2/6/2008Q4 2007$0.40$0.40ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

MEDNAX (NYSE:MD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

MEDNAX (NYSE MD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.40%
Institutional Ownership Percentage: 98.53%
Insider Trading History for MEDNAX (NYSE:MD)
Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

MEDNAX (NYSE MD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/13/2018John C PepiaInsiderSell3,000$58.35$175,050.0039,716View SEC Filing  
12/12/2017John C PepiaInsiderSell3,000$51.58$154,740.0035,569View SEC Filing  
11/3/2017Cesar L AlvarezDirectorSell10,668$42.59$454,350.1244,215View SEC Filing  
9/12/2017John C PepiaInsiderSell3,000$42.85$128,550.0035,569View SEC Filing  
6/14/2017Md Pascal J GoldschmidtDirectorSell1,969$57.57$113,355.3318,072View SEC Filing  
6/1/2017Joseph M CalabroInsiderSell23,327$55.00$1,282,985.00296,379View SEC Filing  
5/5/2017Manuel KadreDirectorBuy21,704$55.79$1,210,866.16111,255View SEC Filing  
5/5/2017Vivian Lopez-BlancoCFOSell7,778$55.82$434,167.9651,319View SEC Filing  
3/16/2017Robert Irwin ValliantDirectorSell5,200$1.10$5,720.00
2/23/2017Enrique SosaDirectorSell10,668$69.65$743,026.2021,923View SEC Filing  
2/17/2017Vivian Lopez-BlancoCFOSell15,164$70.01$1,061,631.6459,097View SEC Filing  
2/16/2017Dominic J AndreanoSVPSell6,000$69.59$417,540.0030,746View SEC Filing  
2/16/2017John C PepiaInsiderSell2,500$69.58$173,950.0031,025View SEC Filing  
2/16/2017Paul G GabosDirectorSell21,336$69.63$1,485,625.6821,923View SEC Filing  
2/10/2017Md Pascal J GoldschmidtDirectorSell25,294$67.82$1,715,439.0814,173View SEC Filing  
2/9/2017Md Carlo A WaldemarDirectorSell5,334$67.90$362,178.6016,589View SEC Filing  
1/17/2017Vivian Lopez-BlancoCFOSell10,000$70.95$709,500.0074,261View SEC Filing  
12/7/2016Md Pascal J GoldschmidtDirectorBuy2,100$66.52$139,692.0013,355View SEC Filing  
9/14/2016Md Pascal J GoldschmidtDirectorSell1,500$65.01$97,515.0012,755View SEC Filing  
6/13/2016Dominic J AndreanoSVPSell3,922$68.80$269,833.6024,746View SEC Filing  
6/8/2016Md Carlo A WaldemarDirectorSell5,334$70.50$376,047.0016,589View SEC Filing  
6/7/2016Karl B WagnerInsiderSell27,482$68.45$1,881,142.90105,932View SEC Filing  
6/1/2016Joseph M CalabroCOOSell28,347$67.78$1,921,359.66253,882View SEC Filing  
6/1/2016Michael D StanleyInsiderSell14,778$67.78$1,001,652.8449,266View SEC Filing  
5/16/2016Dominic J AndreanoSVPSell3,000$68.53$205,590.0021,313View SEC Filing  
5/2/2016Vivian Lopez-BlancoCFOSell9,350$71.22$665,907.0064,083View SEC Filing  
3/11/2016Md Pascal J GoldschmidtDirectorSell3,100$65.00$201,500.0012,479View SEC Filing  
2/29/2016Paul G GabosDirectorSell10,668$67.15$716,356.2020,047View SEC Filing  
12/11/2015Md Pascal J. GoldschmidtDirectorSell5,250$70.99$372,697.509,379View SEC Filing  
9/8/2015Cesar L. AlvarezDirectorSell10,668$81.00$864,108.0029,379View SEC Filing  
8/27/2015Roger Md MedelCEOSell100,000$80.27$8,027,000.001,199,708View SEC Filing  
6/8/2015Karl B WagnerInsiderSell37,820$70.28$2,657,989.60View SEC Filing  
6/3/2015Joseph M CalabroCOOSell108,071$70.51$7,620,086.21View SEC Filing  
3/9/2015Md Pascal J GoldschmidtDirectorSell8,500$71.25$605,625.00View SEC Filing  
2/26/2015Roger Md MedelCEOSell100,000$71.61$7,161,000.00View SEC Filing  
2/20/2015Md Carlo A WaldemarDirectorSell10,668$71.50$762,762.00View SEC Filing  
2/6/2015Dominic J AndreanoSVPSell3,200$70.75$226,400.00View SEC Filing  
2/6/2015Vivian Lopez-BlancoCFOSell8,250$69.95$577,087.50View SEC Filing  
2/2/2015Paul G GabosDirectorSell17,584$68.07$1,196,942.88View SEC Filing  
1/30/2015William C HawkCOOSell3,598$68.50$246,463.00View SEC Filing  
11/14/2014Roger Md MedelCEOSell51,290$62.59$3,210,241.10View SEC Filing  
11/13/2014Roger Md MedelCEOSell63,440$62.55$3,968,172.00View SEC Filing  
11/7/2014Roger Md MedelCEOSell128,833$62.60$8,064,945.80View SEC Filing  
11/5/2014Roger Md MedelCEOSell169,845$62.60$10,632,297.00View SEC Filing  
11/4/2014Roger Md MedelCEOSell15,052$62.52$941,051.04View SEC Filing  
11/3/2014Roger Md MedelCEOSell10,881$62.52$680,280.12View SEC Filing  
10/31/2014Roger Md MedelCEOSell61,592$62.58$3,854,427.36View SEC Filing  
10/30/2014Karl B WagnerInsiderSell40,000$62.50$2,500,000.00View SEC Filing  
10/30/2014Vivian Lopez-BlancoCFOSell8,800$60.00$528,000.00View SEC Filing  
7/30/2014Karl B WagnerInsiderSell80,000$60.00$4,800,000.00View SEC Filing  
6/10/2014Dominic J AndreanoSVPSell2,252$58.48$131,696.96View SEC Filing  
6/6/2014Karl B WagnerInsiderSell44,596$58.53$2,610,203.88View SEC Filing  
6/5/2014William C HawkCOOSell6,911$57.66$398,488.26View SEC Filing  
6/2/2014David A ClarkCOOSell16,230$57.00$925,110.00View SEC Filing  
6/2/2014Michael D StanleyInsiderSell18,006$57.00$1,026,342.00View SEC Filing  
5/9/2014Karl WagnerInsiderSell79,524$57.09$4,540,025.16150,498View SEC Filing  
5/9/2014Md Pascal GoldschmidtDirectorSell30,000$57.11$1,713,300.005,350View SEC Filing  
5/8/2014Joseph CalabroCOOSell137,500$57.06$7,845,750.00226,542View SEC Filing  
2/20/2014Dominic AndreanoSVPSell3,000$61.00$183,000.0016,135View SEC Filing  
2/10/2014Joseph CalabroCOOSell150,000$55.55$8,332,500.00226,542View SEC Filing  
2/10/2014Md Carlo WaldemarDirectorSell10,668$55.40$591,007.205,350View SEC Filing  
11/7/2013Enrique SosaDirectorSell5,334$107.00$570,738.002,675View SEC Filing  
11/7/2013Karl WagnerInsiderSell1,800$107.60$193,680.0075,249View SEC Filing  
9/11/2013William C HawkCOOSell3,162$100.62$318,160.44View SEC Filing  
9/10/2013Dominic J AndreanoSVPSell3,718$99.63$370,424.34View SEC Filing  
8/7/2013Karl WagnerInsiderSell25,000$98.01$2,450,250.0075,249View SEC Filing  
8/2/2013Joseph M CalabroCOOSell36,154$98.57$3,563,699.78View SEC Filing  
6/3/2013David A ClarkCOOSell8,645$91.01$786,781.45View SEC Filing  
6/3/2013Michael D StanleyInsiderSell8,906$91.01$810,535.06View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MEDNAX (NYSE MD) News Headlines

Source:
DateHeadline
MEDNAX 2018 First Quarter Conference Call/Webcast Scheduled for Monday, May 7, 2018MEDNAX 2018 First Quarter Conference Call/Webcast Scheduled for Monday, May 7, 2018
finance.yahoo.com - April 20 at 4:10 PM
THE LIST: Legal battles shaking up Charlotte’s largest physician groupsTHE LIST: Legal battles shaking up Charlotte’s largest physician groups
finance.yahoo.com - April 20 at 10:08 AM
Comparing MEDNAX (MD) and Encompass Health (EHC)Comparing MEDNAX (MD) and Encompass Health (EHC)
www.americanbankingnews.com - April 19 at 9:42 AM
MedTech Stocks Q1 Earnings: Key Predictions for DGX, MD, CHEMedTech Stocks Q1 Earnings: Key Predictions for DGX, MD, CHE
finance.yahoo.com - April 18 at 4:18 PM
MEDNAX Inc (MD) Receives Average Rating of "Hold" from AnalystsMEDNAX Inc (MD) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 18 at 1:34 PM
Head-To-Head Comparison: MEDNAX (MD) vs. Magellan Health (MGLN)Head-To-Head Comparison: MEDNAX (MD) vs. Magellan Health (MGLN)
www.americanbankingnews.com - April 18 at 3:20 AM
$904.13 Million in Sales Expected for MEDNAX Inc (MD) This Quarter$904.13 Million in Sales Expected for MEDNAX Inc (MD) This Quarter
www.americanbankingnews.com - April 16 at 2:37 AM
MEDNAX (MD) and Magellan Health (MGLN) Critical SurveyMEDNAX (MD) and Magellan Health (MGLN) Critical Survey
www.americanbankingnews.com - April 15 at 11:15 AM
MEDNAX (MD) Given a $46.00 Price Target at Jefferies GroupMEDNAX (MD) Given a $46.00 Price Target at Jefferies Group
www.americanbankingnews.com - April 15 at 9:45 AM
Zacks: Brokerages Anticipate MEDNAX Inc (MD) Will Post Earnings of $0.85 Per ShareZacks: Brokerages Anticipate MEDNAX Inc (MD) Will Post Earnings of $0.85 Per Share
www.americanbankingnews.com - April 14 at 5:09 PM
Analyzing Encompass Health (EHC) & MEDNAX (MD)Analyzing Encompass Health (EHC) & MEDNAX (MD)
www.americanbankingnews.com - April 13 at 1:07 AM
Edited Transcript of MD presentation 6-Mar-17 1:40pm GMTEdited Transcript of MD presentation 6-Mar-17 1:40pm GMT
finance.yahoo.com - April 12 at 10:52 AM
MEDNAX (MD) Rating Lowered to Sell at Zacks Investment ResearchMEDNAX (MD) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 11 at 8:58 AM
MedData’s New Patient Financial Platform Solves Inefficient, Costly Revenue Cycle ChallengesMedData’s New Patient Financial Platform Solves Inefficient, Costly Revenue Cycle Challenges
finance.yahoo.com - April 10 at 10:20 AM
Financial Contrast: Encompass Health (EHC) & MEDNAX (MD)Financial Contrast: Encompass Health (EHC) & MEDNAX (MD)
www.americanbankingnews.com - April 10 at 5:29 AM
Analyzing MEDNAX (MD) and Magellan Health (MGLN)Analyzing MEDNAX (MD) and Magellan Health (MGLN)
www.americanbankingnews.com - April 8 at 1:27 PM
MEDNAX (MD) Rating Increased to Hold at Zacks Investment ResearchMEDNAX (MD) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 12:32 PM
Southeast Anesthesiology: ‘Facts will speak’ in lawsuit against Atrium HealthSoutheast Anesthesiology: ‘Facts will speak’ in lawsuit against Atrium Health
finance.yahoo.com - April 6 at 10:33 AM
MEDNAX in Collaboration with Memorial Regional Hospital Earns National Accreditation for Adult Congenital Heart ProgramMEDNAX in Collaboration with Memorial Regional Hospital Earns National Accreditation for Adult Congenital Heart Program
finance.yahoo.com - April 6 at 10:33 AM
Head-To-Head Survey: MEDNAX (MD) and Magellan Health (MGLN)Head-To-Head Survey: MEDNAX (MD) and Magellan Health (MGLN)
www.americanbankingnews.com - April 3 at 1:26 PM
MEDNAX (MD) Lowered to "Sell" at ValuEngineMEDNAX (MD) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - April 3 at 12:11 PM
Head to Head Comparison: Magellan Health (MGLN) & MEDNAX (MD)Head to Head Comparison: Magellan Health (MGLN) & MEDNAX (MD)
www.americanbankingnews.com - April 3 at 9:20 AM
BRIEF-MEDNAX Announces Acquisition Of Pediatric Urology Practice In South FloridaBRIEF-MEDNAX Announces Acquisition Of Pediatric Urology Practice In South Florida
www.reuters.com - April 2 at 10:23 AM
Mednax acquires medical practice with 3 South Florida officesMednax acquires medical practice with 3 South Florida offices
www.bizjournals.com - April 2 at 10:23 AM
MEDNAX (MD) Reports Acquisition of Pediatric Urology Practice in South FloridaMEDNAX (MD) Reports Acquisition of Pediatric Urology Practice in South Florida
www.streetinsider.com - April 2 at 10:23 AM
MEDNAX acquires Pediatric Urology practice in South FloridaMEDNAX acquires Pediatric Urology practice in South Florida
seekingalpha.com - April 2 at 10:23 AM
MEDNAX Inc (MD) Expected to Post Quarterly Sales of $905.91 MillionMEDNAX Inc (MD) Expected to Post Quarterly Sales of $905.91 Million
www.americanbankingnews.com - March 30 at 2:10 AM
MEDNAX Sees Unusually Large Options Volume (MD)MEDNAX Sees Unusually Large Options Volume (MD)
www.americanbankingnews.com - March 29 at 6:54 AM
Critical Analysis: Tabula Rasa HealthCare (TRHC) versus MEDNAX (MD)Critical Analysis: Tabula Rasa HealthCare (TRHC) versus MEDNAX (MD)
www.americanbankingnews.com - March 28 at 5:40 PM
Credit Suisse Takes Neutral Stance On Mednax, Says Buyout Value Reflected In Share PriceCredit Suisse Takes Neutral Stance On Mednax, Says Buyout Value Reflected In Share Price
www.msn.com - March 27 at 4:04 PM
MEDNAX Announces Expansion of Radiology PracticesMEDNAX Announces Expansion of Radiology Practices
finance.yahoo.com - March 27 at 10:22 AM
MEDNAX (MD) Now Covered by Analysts at Credit Suisse GroupMEDNAX (MD) Now Covered by Analysts at Credit Suisse Group
www.americanbankingnews.com - March 27 at 8:45 AM
MEDNAX (MD) PT Set at $50.00 by Jefferies GroupMEDNAX (MD) PT Set at $50.00 by Jefferies Group
www.americanbankingnews.com - March 25 at 12:14 PM
MEDNAX Inc (MD) Receives Consensus Rating of "Hold" from AnalystsMEDNAX Inc (MD) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - March 24 at 1:50 PM
BRIEF-Mednax Says CEO Roger Medels Total Compensation For 2017 Was $7.4 Mln Versus $7.8 Mln In 2016BRIEF-Mednax Says CEO Roger Medel's Total Compensation For 2017 Was $7.4 Mln Versus $7.8 Mln In 2016
www.reuters.com - March 24 at 10:14 AM
MEDNAX (MD) Cut to Hold at Zacks Investment ResearchMEDNAX (MD) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - March 21 at 8:54 PM
BRIEF-Mednax Announces Acquisition Of Pediatric Ophthalmology Practice In WashingtonBRIEF-Mednax Announces Acquisition Of Pediatric Ophthalmology Practice In Washington
www.reuters.com - March 21 at 4:00 PM
MEDNAX Announces Acquisition of Pediatric Ophthalmology Practice in WashingtonMEDNAX Announces Acquisition of Pediatric Ophthalmology Practice in Washington
finance.yahoo.com - March 21 at 11:09 AM
Should Value Investors Pick MEDNAX (MD) Stock?Should Value Investors Pick MEDNAX (MD) Stock?
finance.yahoo.com - March 21 at 11:09 AM
MEDNAX (MD) Given a $58.00 Price Target at Jefferies GroupMEDNAX (MD) Given a $58.00 Price Target at Jefferies Group
www.americanbankingnews.com - March 17 at 4:28 PM
[$$] Medical Wars[$$] Medical Wars
finance.yahoo.com - March 17 at 10:10 AM
John C. Pepia Sells 3,000 Shares of MEDNAX Inc (MD) StockJohn C. Pepia Sells 3,000 Shares of MEDNAX Inc (MD) Stock
www.americanbankingnews.com - March 14 at 7:49 PM
MEDNAX (MD) Upgraded by TheStreet to "B"MEDNAX (MD) Upgraded by TheStreet to "B"
www.americanbankingnews.com - March 14 at 7:20 AM
 Brokerages Anticipate MEDNAX Inc (MD) Will Post Earnings of $0.84 Per Share Brokerages Anticipate MEDNAX Inc (MD) Will Post Earnings of $0.84 Per Share
www.americanbankingnews.com - March 11 at 1:18 PM
What Analysts Recommend for American Renal Associates HoldingsWhat Analysts Recommend for American Renal Associates Holdings
finance.yahoo.com - March 9 at 4:57 PM
Veeva Systems Rides on Strong Q4 & Cloud-Based ApplicationsVeeva Systems Rides on Strong Q4 & Cloud-Based Applications
finance.yahoo.com - March 8 at 10:23 AM
Cerner-Centrus Health to Collaborate, HealtheIntent in FocusCerner-Centrus Health to Collaborate, HealtheIntent in Focus
finance.yahoo.com - March 7 at 4:50 PM
The Manufacturers Life Insurance Company  Acquires 17,163 Shares of MEDNAX Inc (MD)The Manufacturers Life Insurance Company Acquires 17,163 Shares of MEDNAX Inc (MD)
www.americanbankingnews.com - March 6 at 3:12 PM
Cerner Collaborates With Salesforce, Focuses on AI TrendsCerner Collaborates With Salesforce, Focuses on AI Trends
www.msn.com - March 6 at 9:51 AM
Bank of New York Mellon Corp Sells 31,948 Shares of MEDNAX Inc (MD)Bank of New York Mellon Corp Sells 31,948 Shares of MEDNAX Inc (MD)
www.americanbankingnews.com - March 6 at 4:54 AM

SEC Filings

MEDNAX (NYSE:MD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MEDNAX (NYSE:MD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MEDNAX (NYSE MD) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.